icon-folder.gif   Conference Reports for NATAP  
 
  ICAAC 2014 54th Interscience Conference
on Antimicrobial Agents and Chemotherapy
September 5-9, 2014, Washington, DC
Back grey_arrow_rt.gif
 
 
 
Metabolism, Excretion, and Mass Balance of the HIV Integrase Inhibitor, Cabotegravir (GSK1265744) in Humans
 
 
  Reported by Jules Levin
ICAAC - 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 5-9, 2014; Washington, DC
 
A Culp,1 G Bowers,1 E Gould,1 S Ford,1 Y Lou,1 R Pan,2 D Margolis,1 S Piscitelli1
1GlaxoSmithKline, Research Triangle Park, NC; 2GlaxoSmithKline, Collegeville, PA
 
ICAAC: Cabotegravir Injected Every 1, 2, or 3 Months Yields Adequate Troughs in Simulation

ICAAC1.gif

ICAAC2.gif

ICAAC3.gif

ICAAC4.gif

ICAAC5.gif

ICAAC6.gif

ICAAC7.gif